Given the lack of responsiveness of breast cancer to immunotherapy due to absence of a high tumour mutational burden and lymphocytic infiltration [10], the addition of LSD-1 inhibitors to the armamentarium of anti-tumour drugs represents a promising new therapy [121]. Here, KDM1A is linked to breast cancer.